Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma, Myeloid 1Sarcoma 1Rhabdoid Tumor 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Dermatofibrosarcoma 1Central Nervous System Neoplasms 1Blast Crisis 1

Interventions

Radiotherapy 6Doxorubicin 5Nivolumab 4pembrolizumab 3Sunitinib 3Ifosfamide 3Gemcitabine 3Docetaxel 3pazopanib 2Radiation Dose Hypofractionation 2Radiation 2Methotrexate 2Ipilimumab 2Cisplatin 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1temsirolimus 1spartalizumab 1sintilimab 1ribociclib 1regorafenib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1itacitinib 1fludarabine 1eribulin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Histiocytoma, Malignant Fibrous × Razoxane × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡